Compare RNA & DOCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNA | DOCS |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 12.3B |
| IPO Year | 2020 | 2021 |
| Metric | RNA | DOCS |
|---|---|---|
| Price | $72.61 | $37.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 20 |
| Target Price | ★ $69.26 | $67.20 |
| AVG Volume (30 Days) | 1.7M | ★ 2.6M |
| Earning Date | 02-26-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.88 |
| EPS | N/A | ★ 1.25 |
| Revenue | $20,868,000.00 | ★ $621,329,000.00 |
| Revenue This Year | $88.12 | $15.40 |
| Revenue Next Year | $18.11 | $11.14 |
| P/E Ratio | ★ N/A | $30.94 |
| Revenue Growth | ★ 106.27 | 20.21 |
| 52 Week Low | $21.51 | $37.33 |
| 52 Week High | $72.74 | $85.21 |
| Indicator | RNA | DOCS |
|---|---|---|
| Relative Strength Index (RSI) | 65.35 | 27.67 |
| Support Level | $72.40 | $37.33 |
| Resistance Level | $72.66 | $41.88 |
| Average True Range (ATR) | 0.17 | 1.44 |
| MACD | -0.10 | -0.15 |
| Stochastic Oscillator | 71.57 | 2.63 |
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.